Aldeyra readies market for bad news as FDA nears decision date

17 October 2023
eye_ophthalmics_ophthalmology_big-1

A formal  disclosure from Aldeyra Therapeutics (Nasdaq: ALDX), suggesting a potential rejection from the US Food and Drug Administration, has stripped around 70% from the firm’s share price.

The filing with the US Securities and Exchange Commission follows the receipt of minutes from a late-cycle review meeting, where the agency discussed the firm’s submission for reproxalap.

Developed for the treatment of the signs and symptoms of dry eye disease, Aldeyra’s lead candidate has  faced setbacks already, including the failure of the Phase III  TRANQUILITY study in 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical